UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000056193 |
|---|---|
| Receipt number | R000064032 |
| Scientific Title | Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis |
| Date of disclosure of the study information | 2024/11/20 |
| Last modified on | 2024/12/03 12:06:33 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis
Acronym
A Literature Review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis
Scientific Title
Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis
Scientific Title:Acronym
Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis
Region
| Japan |
Condition
Condition
Rheumatoid arthritis
Classification by specialty
| Clinical immunology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this review is to determine of the clinical features and factors associated with the seroconversion of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis.
Basic objectives2
Others
Basic objectives -Others
The purpose of this review is to determine of the clinical features and factors associated with the seroconversion of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Seroconversion of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis.
Key secondary outcomes
Factors associated with the development of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)Original paper evaluating the development of anti-CCP antibody after diagnosis of rheumatoid arthritis
Key exclusion criteria
1)Unable to assess frequency of Anti-CCP antibody seroconversion
2)Reviews, meta-analysis papers and Research plan
3)Conference abstracts
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | Masaru |
| Middle name | |
| Last name | Kato |
Organization
University of Toyama Faculty of Medicine
Division name
The First Department of Internal Medicine
Zip code
930-0194
Address
2630 Sugitani, Toyama, Japan.
TEL
076-434-7287
ktmasaru@med.u-toyama.ac.jp
Public contact
Name of contact person
| 1st name | Ryoko |
| Middle name | |
| Last name | Asano |
Organization
University of Toyama Faculty of Medicine
Division name
The First Department of Internal Medicine
Zip code
930-0194
Address
2630 Sugitani, Toyama, Japan.
TEL
076-434-7287
Homepage URL
aryoko@med.u-toyama.ac.jp
Sponsor or person
Institute
First Department of Internal Medicine, University of Toyama
Institute
Department
Personal name
Funding Source
Organization
First Department of Internal Medicine, University of Toyama
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
First Department of Internal Medicine, University of Toyama
Address
University of Toyama Faculty of Medicine
Tel
076-434-7287
aryoko@med.u-toyama.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 11 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
14
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2024 | Year | 11 | Month | 03 | Day |
Date of IRB
| 2024 | Year | 11 | Month | 03 | Day |
Anticipated trial start date
| 2024 | Year | 11 | Month | 22 | Day |
Last follow-up date
| 2024 | Year | 11 | Month | 29 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
In this is a systematic review, we searched PubMed, the Cochrane Library, and Scopus to screen for articles.The inclusion criteria is that evaluated the seroconversion of anti-CCP antibody after the diagnosis of rheumatoid arthritis. The exclusion criteria were 1) articles that could not evaluate the frequency of the development of anti-CCP antibody, 2) review articles, meta-analysis articles, and research protocols, and 3) conference abstracts. The primary outcome was the development of anti-CCP antibodies after the diagnosis of rheumatoid arthritis.
Management information
Registered date
| 2024 | Year | 11 | Month | 19 | Day |
Last modified on
| 2024 | Year | 12 | Month | 03 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064032
